Trial purpose
Diagnostic
Tumor type
Lung cancer
Age
18+
Clinical summary
Summary
The purpose of this study is to determine the practicality of a new blood test called droplet digital PCR (ddPCR) to detect circulating tumour DNA in people with early stage lung cancer.
You may be eligible for this study if you are an adult who has ssuspected or proven non-small cell lung cancer.
Participants will provide blood samples and a sample of lung tumour at the time of surgery. Participants will be reviewed one month post-surgery and then every 6 months for 3 years, with a clinical review, CT scan, and blood test completed at each follow-up. Participants will be reviewed at 4 and 5 years with a clinical review and CT scan.
It is hoped this research will enable doctors in the future to use this new blood test to better predict outcomes of cancer surgery in order to determine the best post-operative treatment required for each individual participant.
Conditions
This trial is treating people with stage I-IIIA non-small cell lung cancer requiring surgery
Eligibility
Inclusion
1. Patient with suspected or proven stage I – IIIA NSCLC requiring surgical resection.
2. Availability of tumour tissue for the purpose of DNA analysis, (either prior to or during surgery) with enough tumour material of at least 50% tumour purity to yield sufficient DNA (1-2ug) for whole genome sequencing
3. Age greater than or equal to 18
Exclusion
1. Persons with a cognitive impairment, intellectual disability or mental illness who are not competent to consent.
2. Patients unfit for lung cancer resection.
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- Your cancer has not spread to other parts of the body (localised).
Exclusion
- You have certain types of non-cancer medical conditions.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:
Trial sponsor
Associate Professor Alexander Dobrovic
Scientific Title
Droplet digital PCR – using chromosome rearrangements as tumour-specific markers in disease monitoring for lung cancer. Determining the utility of ctDNA post-surgery as a marker of metastatic or persistent disease up to 36 months after surgery
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information